
|Articles|September 12, 2017
Tufts Finds Cardiovascular Drug Approval Rate in the US Fell
Advertisement
Tufts Center for the Study of Drug Development recently completed a study, which was released September 12. The findings show that even though the rate at which investigational drugs received marketing approval in the U.S. has declined in recent years, the cardiovascular approval rate trailed other drug approvals, while the time needed to develop cardiovascular drugs rose.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Takeda’s Phase III TIDES Trial Confirms Long-Term Efficacy and Safety of Qdenga Dengue Vaccine
2
Utilizing Tech Tools to Accelerate Drug Development
3
Streamlining Clinical Data to Reduce Site and Participant Burden
4






.png)



.png)



.png)
.png)
